文献速递白血病

纠正Bcl-x剪接可改善慢性髓性白血病细胞及小鼠模型对伊马替尼的应答

Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse models.
PubMed 文献 · Br J Haematol · 2020-03-19

该研究针对慢性髓性白血病(CML)伊马替尼(IM)耐药问题,利用vMO纠正Bcl-x异常剪接,在K562细胞、耐伊马替尼K562/G01细胞及CML异种移植模型中观察对IM敏感性的影响。结果显示纠正Bcl-x剪接可增强IM诱导的生长抑制和凋亡,并在体内增强IM抗肿瘤效果。

要点

  • vMO可有效恢复CML细胞中异常的Bcl-x剪接
  • 纠正Bcl-x剪接增强IM对K562及K562/G01细胞的生长抑制和凋亡
  • CML异种移植模型中纠正Bcl-x剪接增强IM抗肿瘤效果

核心结论

  • vMO与IM联用可在体外和体内有效提高CML细胞对IM的敏感性。
  • Bcl-x剪接可作为IM耐药CML化疗增敏的候选靶点。

研究设计与样本

  • 研究使用vMO纠正CML细胞中Bcl-x异常剪接,并在K562细胞、耐伊马替尼K562/G01细胞系及CML异种移植小鼠模型中评估对IM的应答。

主要发现

  • CCK-8细胞活力检测和流式细胞术显示,恢复Bcl-x剪接增加IM诱导的K562细胞生长抑制和凋亡。
  • 在耐伊马替尼CML细胞系K562/G01中观察到更显著的类似现象。
  • CML异种移植模型证明,体内纠正Bcl-x剪接也可增强IM的抗肿瘤效果。

临床怎么用

  • 对于IM耐药的CML,纠正Bcl-x剪接可能作为增敏策略与IM联用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Imatinib mesylate (IM) resistance has become a major clinical problem for chronic myeloid leukaemia (CML). It is known that Bcl-x splicing is deregulated and is involved in multiple malignant cancer initiation and chemotherapy resistance, including CML. The aim of the present study was to correct the abnormal splicing of Bcl-x in CML and investigate the subsequent malignant phenotype changes, especially response to IM. The aberrant Bcl-x splicing in CML cells was effectively restored using vivo-Morpholino Antisense Oligomer (vMO). CCK-8 cell viability assay and flow cytometry showed that restoring of Bcl-x splicing increases IM-induced growth inhibition and apoptosis of K562 cells. Moreover, a more significant similar phenomenon was observed in imatinib-resistant CML cell lines K562/G01. Finally, establishment of CML xenograft model had also proved that correcting Bcl-x splicing in vivo can also enhance the anti-tumor effect of IM. Our findings suggest that vMO co-operating with IM can effectively increase the sensitivity of CML cells to IM both in vitro and in vivo, and Bcl-x splicing could become good candidates for chemotherapy-sensitized target in IM-resistant CML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhang J, Wang Y, Li SQ, et al. Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse models. Br J Haematol. 2020. PMID: 32189339. doi:10.1111/bjh.16472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。